Recent evidence links gut dysbiosis and the gut-brain axis to the pathophysiology of Parkinson’s disease (PD), which is considered one of the most common neurodegenerative illnesses and is characterized by motor symptoms and a gradual loss of nigral dopaminergic neurons. Canagliflozin (CANA), a sodium–glucose cotransporter-2 inhibitor with emerging anti-inflammatory and antioxidant properties, has recently gained attention for...